Developing Next Generation Psychedelic Medicines to Treat Mental Illness

Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.

Join Newsletter

About us

The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin 5-HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 has recently entered Phase I trials.

Read more

Lophora Founders Team at BioInnovation Institute (October 2020). From left: Emil Märcher-Rørsted, Jesper Langgaard Kristensen, Bo Tandrup, Anders Asbjørn Jensen.

News

Lophora Raises $3 million and Recieves Approval from EMA to Initiate Phase I Clinical Trial for LPH-5

Lophora featured in Medwatch (in Danish) Read the article

Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5

After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has

Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that

Companies attract venture funding for redesigned psychedelic drugs

CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 in the landscape of next generation psychedelics. Read the

Next-generation psychedelics: should new agents skip the trip?

CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next generation psychedelics. https://www.nature.com/articles/s41587-024-02285-1

Lophora Liber herbarium

Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders,

Get Exclusive Updates from Lophora – Subscribe to Our Newsletter